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Abstract
Pleuropulmonary blastoma (PPB) is the most frequent pediatric lung tumor and
often the first indication of a pleiotropic cancer predisposition, DICER1
 syndrome, comprising a range of other individually rare, benign and malignant
tumors of childhood and early adulthood. The genetics of -associatedDICER1
tumorigenesis are unusual in that tumors typically bear neomorphic missense
mutations at one of five specific “hotspot” codons within the RNase IIIb domain
of , combined with complete loss of function (LOF) in the other allele.DICER 1
We analyzed a cohort of 124 PPB children for predisposing  mutationsDICER1
and sought correlations with clinical phenotypes. Over 70% have inherited or 
 germline LOF mutations, most of which truncate the  opende novo DICER1
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1 germline LOF mutations, most of which truncate the  opende novo DICER1
reading frame. We identified a minority of patients who have no germline
mutation, but are instead mosaic for predisposing  mutations.DICER1
Mosaicism for RNase IIIb domain hotspot mutations defines a special category
of  syndrome patients, clinically distinguished from those with germlineDICER1
or mosaic LOF mutations by earlier onsets and numerous discrete foci of
neoplastic disease involving multiple syndromic organ sites. A final category of
patients lack predisposing germline or mosaic mutations and have disease
limited to a single PPB tumor bearing tumor-specific RNase IIIb and LOF
mutations. We propose that acquisition of a neomorphic RNase IIIb domain
mutation is the rate limiting event in -associated tumorigenesis, andDICER1  
that distinct clinical phenotypes associated with mutational categories reflect
the temporal order in which LOF and RNase IIIb domain mutations are acquired
during development.
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Introduction
Pleuropulmonary blastoma (PPB) is the most common primary 
lung cancer of childhood (OMIM #601200)1,2. Early PPB (type I) 
presents as lung cysts that are at risk for transformation into high 
grade sarcomas, which may have both cystic and solid components 
(PPB type II) or be entirely solid (PPB type III)2,3. Not all PPB type I 
cysts progress to sarcoma; those that do not are designated type Ir 
(regressed)1,3. The genetic and epigenetic events responsible for ini-
tiation of cyst formation and subsequent progression to sarcoma 
are just beginning to be understood3–6. PPB is pathognomonic for a 
childhood cancer syndrome that features a range of other benign and 
malignant neoplasms including ovarian Sertoli-Leydig cell tumor 
(SLCT), cystic nephroma (CN) and renal sarcoma or Wilms tumor, 
nodular hyperplasia and carcinoma of the thyroid gland, nasal 
chondromesenchymal hamartoma (NCMH), embryonal rhabdomy-
osarcoma (ERMS), pituitary blastoma and pineoblastoma2,4,7–30. We 
previously identified inherited loss of function (LOF) mutations 
in DICER1 (OMIM #606241) as the major genetic factor in this 
syndrome4. DICER1 syndrome thus became the first cancer predis-
position associated with a systemic defect in microRNA (miRNA) 
processing.
The DICER1 gene encodes an RNase III-family endonuclease that 
cleaves precursor microRNAs (pre-miRNA) into active miRNA31,32. 
Sequencing studies of syndromic tumors have revealed biallelic, 
compound mutations of DICER16,11,15,21,26,28–30,33–35. Generally, one 
allele (often germline) bears a nonsense or frame-shift mutation 
predicted to cause full loss of function (LOF), and one allele bears a 
missense mutation in the DICER1 RNase IIIb domain. Biallelic LOF 
mutations have not been identified in PPB, suggesting that retention 
of some miRNA processing function is usually required for tumor 
survival6,35. RNase IIIb missense mutations in DICER1 syndrome 
tumors affect five “hotspot” codons that encode key amino acids 
in the metal-binding catalytic cleft of the nuclease domain: E1705, 
D1709, G1809, D1810 and E18136,26,29,30,33–35. Amino acid substi-
tutions at these positions cause neomorphic DICER1 function in 
miRNA processing, such that cleavage of mature 5p miRNAs from 
the 5’ end of pre-miRNA hairpin structures fails, while mature 3p 
miRNAs continue to be cleaved from the 3’ end normally6,26,33,35,36. 
The high overall ratio of 5p to 3p mature miRNAs seen in nor-
mal tissues is essentially inverted in DICER1 tumors, suggesting 
that uncleaved 5p miRNAs are rapidly degraded6. Depletion of 5p 
miRNAs alters expression of numerous downstream target mRNAs 
across the exome, including some critical for embryogenesis or 
tumor suppression33,36. The pleiotropic nature of DICER1 syndro-
mic disease likely reflects the diverse array of genes regulated by 
miRNAs during organ development and in differentiated tissues.
Clinical features of DICER1 syndrome are highly variable with 
regard to age at first occurrence of neoplastic disease, the number 
of discrete foci of disease that develop over time, and the specific 
organ sites involved. As a step toward understanding the basis of 
clinical variability, we explored the spectrum of predisposing 
DICER1 mutations in a large cohort of PPB/DICER1 syndrome 
patients. Correlation of genotypes with clinical features revealed 
a distinctive phenotype of early onsets and extensive, multifocal 
disease in patients who are mosaic for hotspot missense mutations 
in the RNase IIIb domain. We propose that the extreme phenotypes 
of this patient group are attributable to the order in which allelic 
DICER1 mutations were acquired during development, i.e., an 
RNase IIIb hotspot missense mutation acquired early in embryo-
genesis and subsequently unmasked by LOF mutations or loss of 
the second allele. Understanding how the interplay of RNase IIIb 
missense and LOF mutations influences the expression of syndro-
mic neoplasias can aid diagnosis at early stages, when they are most 




PPB patients (n = 124) and family members were ascertained 
through the International PPB Registry (IPPBR). Inclusion into 
this study required a pathologic diagnosis of PPB verified by cen-
tral review (LPD, DAH). All subjects gave written consent for 
molecular and family history studies, as approved by the Human 
Research Protection Offices at Washington University in St. Louis 
(HSC#04-1154), Children’s Hospitals and Clinics of Minnesota 
(IRB#98107), and Children’s National Medical Center (IRB#4603; 
Pro0315). For families with more than one affected member, only 
data from the initial proband is included. Medical history and bio-
logical samples were collected and prepared for analysis as previ-
ously described4,30. Tumor tissue was available for sequencing from 
a subset of patients. For two of these cases, DNA was isolated from 
unstained tissue on glass slides using the Pinpoint Slide DNA Isola-
tion System (Zymo, Irvine, CA).
Definition of “disease foci”
Clinical data was abstracted from medical records and imaging 
studies. All children had pathologic confirmation of PPB. In addi-
tion, lung cysts, kidney cysts, CN, NCMH, SLCT, ERMS, thyroid 
cancer or nodules, pineoblastoma and/or pituitary blastoma were 
defined as evidence of syndromic disease. Lung cysts that were dis-
tinctly separate (anatomically separate in same lobe or in different 
lobes) were counted individually.
Mutation testing
Initial sequencing of blood and saliva DNA samples was by stand-
ard Sanger methods described previously4 or by a commercial labo-
ratory (Ambry Genetics, Aliso Viejo, CA). Low-frequency variants 
were detected and quantified by targeted next-generation sequenc-
ing (NGS) using a custom multiplex PCR panel for DICER1 coding 
regions (Ion Torrent Ampliseq, Life Technologies, Grand Island, 
NY, USA) (Table S1)30. NGS was performed on an Ion Torrent 318 
v2 chip (ION PGM Sequencing 200 kit v2, Life Technologies) with 
an average of 6 samples per chip, to achieve an average depth of 
coverage of 3000 filtered reads. Signal processing, mapping and 
quality control were performed with Torrent Suite software v.4.0.2 
(Life Technologies). Variant calls were made using the Torrent Vari-
ant Caller Plugin v.4.0, with somatic low stringency mutation work-
flow and default settings. BAM files of raw reads were reviewed 
using Integrative Genomics Viewer v2.337,38.
Annotation of sequence variants and the spectrum of 
possible mutations
DICER1 sequence variants were annotated with Alamut Batch 
software (Interactive Biosoftware, Rouen, France), with reference 
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to DICER1 transcript record NM_177438.2. Nonsense, frameshift 
and canonical splice-site mutations were considered loss of function 
(LOF). Missense variants affecting codons 1705, 1709, 1809, 1810 
and 1813 in the RNase IIIb domain were classified as “hotspot” 
mutations. For variants assayed by NGS, allele frequencies were 
calculated from filtered read counts. The SIFT algorithm was used 
to assess potential significance of novel missense mutations39–41. 
All variants identified were deposited into ClinVar (accession num-
bers SCV000195560-SCV000195643). The numbers of possible 
single-nucleotide changes that can produce amino acid substitu-
tions at the five hotspot codons or nonsense mutations anywhere in 
the DICER1 open reading frame, or disrupt canonical splice sites, 
were compiled from DICER1 transcript record NM_177438.2 and 
genomic record NG_016311.1.
NanoString genomic copy number assay
Molecular probes for NanoString Copy Number Assay at the 
DICER1 locus were developed in collaboration with NanoString 
Technologies, Inc., Seattle, WA (Table S2). Genomic DNA was 
fragmented and hybridized using the nCounter Prep Station, and 
hybridization signals quantified using the nCounter Digital Ana-
lyzer, according to NanoString’s recommendations. Preliminary 
analysis and quality control of the data were performed using 
nSolver Analysis Software version 1.1 (NanoString) with default 
copy number variation (CNV) analysis settings. CNVs were con-
firmed with high-density CNV array hybridization in a commercial 
laboratory (Prevention Genetics, Marshfield, WI).
Statistical analyses
The number of disease foci per patient and the age at DICER1 syn-
drome diagnosis were compared between mutation categories using 
nonparametric tests, due to the skewness of both clinical features 
and to the unbalanced sample sizes. Kruskal-Wallis tests were used 
to compare medians among the four mutation categories. Where 
a significant overall association was found, pair-wise post-hoc 
Wilcoxon rank sum tests were used to compare medians, and result-
ing p-values adjusted for multiple comparisons using the Sidak 
method. A p-value of 0.05 was considered statically significant and 
all analyses were performed using Stata V13 (College Station, TX).
Results
Most predisposing DICER1 mutations are inherited loss of 
function (LOF) mutations
Our overall approach to detecting and categorizing predispos-
ing DICER1 mutations in PPB children is shown schematically 
in Figure 1. We identified germline, heterozygous DICER1 muta-
tions in 90 of the 124 probands in our cohort (72.6%; Table 1, 
Table S3). Nearly all (89) were detected by Sanger sequencing 
of exonic PCR amplicons. For one child in whom no mutation 
was detected by Sanger sequencing, blood DNA was probed by 
NanoString hybridization, which indicated deletion of one copy of 
exon 24. High-density CNV array hybridization was used to con-
firm a heterozygous deletion of ~ 1.1 kb, comprising all of exon 
24 and parts of the flanking introns (c.5096-498_5364+356del). 
Paternal DNA was positive for the deletion, which was anticipated 
as this child has an uncle with CN. Only one previous instance of 
a large, intragenic deletion as a germline DICER1 mutation has 
been reported, which suggests such mutations are very rare42. The 
actual prevalence of large deletions is difficult to estimate because 
they are not readily detected by the targeted sequencing strategies 
applied for mutation screening in this study and most others.
The spectrum of germline mutations is dominated by truncating, 
LOF mutations (Figure 2). These are mainly single-nucleotide sub-
stitutions that produce new stop codons (33 cases, 37%) and small 
insertions or deletions (indels) within exons that shift reading frame 
(44 cases, 49%). Seven mutations of consensus splice sites occur 
in our cohort; of which six are predicted to cause exon skipping 
during transcript splicing with resulting frameshift. The remaining 
splice site mutation, c.1752+1delG, is at the 5’ end of intron 10. 
Skipping of exon 10 would cause in-frame deletion of 81 amino 
acids near the end of the helicase domain. In all, 84 of 90 germline 
DICER1 mutations discovered in patients (93%) truncate the open 
reading frame before the end of the critical RNase IIIb domain, and 
are thus predicted to result in complete loss of DICER1 protein 
function even if the message escapes nonsense-mediated decay. Six 
non-truncating germline mutations were identified, including the 
intron 10 splice site mutation described above and five non-hotspot 
missense changes: I582T, L1583R and G1708E (each seen once) 
and D1822V (identified in two patients) (Table S4). The I582T sub-
stitution is at the distal end of the helicase domain (Figure 2), the 
role of which is unclear. L1583R is within the RNase IIIa domain 
and segregates with disease in a family4. The G1708E and D1822V 
mutations both fall within the RNase IIIb domain, near the metal-
binding catalytic site. These two missense mutations are predicted 
to compromise protein function by the SIFT algorithm but their pre-
cise functional significance in DICER1 is unknown39–41.
DNA was available from both parents for 77 children with germline 
mutations, and Sanger sequencing of parental DNA was sufficient 
to confirm 67 of the mutations (87%) as inherited. Mutations in 
the ten patients whose parents had no DICER1 mutation detected 
by Sanger sequencing were provisionally considered de novo. To 
confirm this, targeted next generation sequencing (NGS) was per-
formed in eight of the ten trios, yielding mutant allele frequencies 
between 42.0% and 57.1% in the probands but no conclusive evi-
dence of the variants in parental blood. There were no statistically 
significant differences between de-novo and inherited germline 
LOF patients with respect to age at onset, numbers of disease foci 
or survival.
Penetrance of familial DICER1 LOF mutations was far from com-
plete. Of the 67 families in this cohort with segregating LOF muta-
tions, 29 include parents or siblings who are confirmed as mutation 
carriers but have no history of syndromic disease (Table S5). True 
penetrance is difficult to estimate because we have limited knowl-
edge of how many germline DICER1 mutation carriers are phe-
notypically normal, as only a subset with overtly affected family 
members have been ascertained. Moreover, subclinical disease 
is common. Preliminary data from an ongoing NCI-sponsored 
DICER1 family history study indicate that ~ 87% of otherwise 
asymptomatic individuals with confirmed DICER1 mutations have 
thyroid nodules detectable by ultrasound and ~ 43% have lung cysts 
detectable by CT scan (D.R. Stewart and L. Doros, unpublished).
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Among children with germline LOF mutations, age at first diagnosis 
of PPB or other syndromic disease was typically one to five years (70 
of 90 patients), but this ranged from diagnosis within days of birth 
to as late as eighteen years. The most frequent syndromic condition 
after PPB was cystic nephroma, followed by thyroid disease (nodu-
lar hyperplasia or carcinoma), nasal chondromesenchymal hamar-
tomas and embryonal rhabdomyosarcomas (Table 1, Table S5). The 
number of discrete disease foci per patient ranged as high as five 
or six (in two patients), but the majority of children in this group 
had experienced no more than two at the time of their most recent 
exam, and nearly half had only a single PPB tumor. None of the six 
patients with non-truncating germline mutations had unusual clinical 
features and as a group they were not distinguishable from patients 
with truncating mutations. Table S6 provides data on somatic hotspot 
mutations identified in all available tumors of PPB children.
Approximately 10% of predisposing DICER1 mutations are 
mosaic rather than germline
We and others have previously described biallelic DICER1 muta-
tions in tumors of children who apparently have no germline muta-
tion, inherited or de novo6,14,35. Because PPB children are typically so 
young when affected, we hypothesized that at least some cases of this 
Figure 1. Study design – Detection and categorization of DICER1 mutations in PPB probands. A cohort of 124 children diagnosed 
with pleuropulmonary blastoma (PPB) was screened for predisposing DICER1 mutations by targeted Sanger sequencing and/or low-depth, 
next-generation sequencing (NGS) of DNA amplified from peripheral blood cells, saliva (buccal cells) or non-neoplastic surgical specimens. 
Sequenced PCR amplicons covered the 26 coding exons of the DICER1 open reading frame and flanking splice signals. DICER1 coding 
sequence or splice site mutations detected at approximately heterozygous frequency in blood or normal tissue cells were categorized as 
germline mutations. For patients in whom screening revealed no germline mutation, blood and/or normal tissues were analyzed for the 
presence of intragenic deletions or larger genomic alterations using NanoString copy number assay and CNV array, and for coding or 
splice site mutations present at low allele frequencies using high-depth NGS on the Ion Torrent platform. Wherever possible, matched tumor 
specimens were also sequenced on the Ion Torrent platform. Low-frequency DICER1 mutations detected in multiple normal and/or tumor 
samples, or in primary tumors of multiple organs, were categorized as mosaic mutations. Mosaic mutations were further categorized as loss-
of-function (LOF) or RNase IIIb domain hotspot missense mutations. Patients for whom both LOF and hotspot mutations were identified in a 
single tumor, but not found in blood or normal tissue samples, were categorized as having tumor-specific, biallelic DICER1 mutations.
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Number of patients 90 5 5 12
Sex distribution
   Male 44 3 2 10
   Female 46 2 3 2
Age at first diagnosis, monthsa
   Median (range) 35 (0–227) 25 (12–46) 11 (0–15) 33 (24–139)
   Mean (standard deviation) 36 (31) 27 (12) 9 (6) 42 (31)
   P-value, vs. germline groupd – 0.97 0.048 0.99
Disease foci distribution
   Lung - cysts, PPB 90 5 5 12
   Kidney - cysts, cystic nephroma 12 0 4 0
   Kidney - Wilms tumor 1 0 0 0
   Thyroid - nodular hyperplasia 4 0 2 0
   Thyroid - cancer 4 0 1 0
   Nasal cavity - NCMH 5 0 2 0
   Ovary - Sertoli-Leydig cell tumor 3 0 2 0
   Uterine cervix - ERMS 4 0 0 0
   Urinary bladder - ERMS 2 0 0 0
   Pineoblastoma 1 0 1 0
   Ciliary body medulloepithelioma 1 0 1 0
   Small intestine - juvenile polyps 0 0 4 0
PPB type distribution
   Type IR 9 0 5c 0
   Type I 25 2 0 1
   Type II 31 1 1c 6
   Type III 25 2 0 5
Number of disease foci per patientb
   Median (range) 2 (1–6) 2 (1–2) 14 (10–24) 1 (1–1)
   Mean (standard deviation) 1.8 (1.0) 1.6 (0.5) 16.8 (6.3) 1 (0.0)
   P-value, vs. germline groupd – 0.99 0.0006 0.0072
Survival, number of patients (months)
   Alive (median age at present) 80 (100) 3 (46) 5 (96) 10 (85)
   Deceased (median age at death) 10 (60.5) 2 (64.5) 0 2 (57)
Abbreviations: PPB pleuropulmonary blastoma; NCMH nasal chondromesenchymal hamartoma; ERMS 
embryonal rhabdomyosarcoma.
a. Age at first clinical presentation with PPB or other DICER1 syndrome pathology. 
b. Total number of discrete disease foci, as defined in Subjects and Methods. 
c. One patient with both type IR and type II PPB. 
d. Medians compared using a Kruskal-Wallis test; post-hoc pair-wise tests adjusted for multiple comparisons.
Page 6 of 21
F1000Research 2015, 4:214 Last updated: 24 JUL 2015
Figure 2. The spectrum of predisposing loss-of-function mutations in PPB/DICER1 syndrome. A linear schematic of the DICER1 open 
reading frame is shown with annotated functional domains represented to scale. Sequence changes identified as inherited or de novo 
germline mutations in 90 PPB/DICER1 syndrome patients are indicated by position along the coding sequence. Mutations linked to the 
schematic by two, three or four fine lines are those discovered in a corresponding number of individuals from unique families.





c.735-1_741delGGTATACTinsA; intron 6, 3'ss
c.1144G>T; p.E382*
c.1202dupA; p.Y401fs*


































c.2040+1G>T; intron 12, 5'ss
c.2247C>A; p.Y749*














































Page 7 of 21
F1000Research 2015, 4:214 Last updated: 24 JUL 2015
kind reflect mosaicism, i.e., a mutation present in some but not all 
cells of the body, because it occurred during post-zygotic embryonic 
development rather than being present in the zygote (as a germline 
mutation would be). To explore this possibility, we performed tar-
geted, high-depth NGS of DICER1 coding exons in DNA from blood 
and/or other normal tissues of children who had tested negative for 
germline mutation by Sanger sequencing, and in matched samples 
of tumor tissue where available. We categorized a DICER1 mutation 
detected by NGS as mosaic when the following criteria were met: i. 
The mutation was evidently not a constitutional, germline allele 
because it was present at sub-heterozygous frequency (arbitrarily 
taken as below 35% of reads) in peripheral blood and/or other nor-
mal tissue samples. ii. The mutation was evidently not specific to a 
tumor, because the same mutant allele was detected in one or more 
normal, non-neoplastic tissue samples, OR, the same mutant allele 
was detected in multiple primary tumors arising in different organs 
(Figure 1). We identified ten children with predisposing mosaicism 
for either LOF or RNase IIIb hotspot mutations (Table 1).
Mosaic LOF mutations were detected in five children, at frequen-
cies that ranged from 1.1% to 17.2% of allelic reads in DNA from 
blood, saliva or normal fibroblasts (Table S7). For three of these 
children, archival PPB tumor tissue was available, and in each the 
LOF mutation was present, as was an RNase IIIb domain hotspot 
mutation. Two of the five children with mosaic LOF mutations had 
a single focus of disease in a lung. The other three children each had 
two foci of disease, also restricted to the lungs. It might be antic-
ipated that children bearing mosaic LOF mutations tend to have 
fewer disease foci than those with germline LOF mutations because 
the number of cells at risk for second hits is generally lower. No 
statistically significant difference of this kind can be discerned from 
the five mosaic LOF children in our cohort, but notably, none have 
developed syndromic tumors other than PPB. As this was not a pop-
ulation study, we cannot estimate how many persons with mosaic 
LOF mutations are asymptomatic but, by analogy to the low pen-
etrance of familial LOF mutations, it could be a large proportion.
Five children harbored mosaic RNase IIIb domain hotspot missense 
mutations, detected in multiple primary neoplasms and/or non-
neoplastic tissues (Table 2). None had family members with fea-
tures of DICER1 syndrome, and the RNase IIIb hotspot mutations 
found in probands were not detected in parental blood, consistent 
with a postzygotic origin. NGS of tumor tissues from these chil-
dren identified somatic LOF mutations or allele loss in some but 
not all specimens, with the caveat that allele loss can be difficult to 
detect in specimens with low tumor purity (i.e., PPB Type Ir, CN and 
NCMH). For one mosaic hotspot patient, specimens of a thyroid car-
cinoma and two separate ovarian Sertoli-Leydig cell tumors (SLCT) 
were available for NGS. The thyroid carcinoma and one SLCT had 
lost the second DICER1 allele, but the other SLCT had instead sus-
tained a frameshift mutation (Table 2). This is consistent with under-
lying mosaicism for the RNase IIIb hotspot mutation and subsequent 
acquisition of independent LOF mutations in each tumor site.
Mosaic RNase IIIb hotspot mutations are associated with 
early-onset, multifocal disease
The five children with mosaic RNase IIIb domain hotspot mutations 
shared unusual clinical features. All were diagnosed with DICER1 
syndrome early; within 15 months of birth. All presented with mul-
tiple cysts of the lungs and/or kidneys, which were accompanied 
or followed in all cases by multiple DICER1 syndromic tumors 
(Figure 3). Four of the five had CN as well as PPB. Other tumors 
included SLCT, thyroid nodular hyperplasia or carcinoma, NCMH, 
ciliary body medulloepithelioma and pineoblastoma. In addition, 
four of the five children experienced episodes of intestinal intus-
susception, which in three cases were associated with polyps of the 
small intestine discovered upon surgical intervention. Total num-
bers of discrete disease foci per patient were extraordinarily high, 
ranging from a minimum of 10 to as many as 24. Despite the small 
number of patients in this group, statistical analysis confirms clini-
cal impressions that they are distinct from those with predisposing 
LOF mutations. Mean age at first DICER1 syndrome diagnosis was 
significantly earlier, and both mean and median numbers of dis-
ease foci are significantly greater in children with mosaic RNase 
IIIb mutations (Table 1). The association with juvenile-type intes-
tinal polyps and intussusception is a novel feature of children with 
mosaic RNase IIIb hotspot mutations, not previously seen in chil-
dren with other categories of DICER1 mutation.
Four of the five children with mosaic DICER1 hotspot mutations 
presented with cystic PPB (type I/IR) rather than sarcomatous dis-
ease (type II or type III) and all five have survived to date. How-
ever, this does not indicate a benign clinical course. Though all five 
hotspot mosaic children are alive, their clinical experiences have 
been complicated and arduous (Figure 3). Each has undergone mul-
tiple major surgeries and chemotherapies with concomitant mor-
bidities. One child is alive with recurrent disease at last follow-up.
Tumor-specific, biallelic DICER1 mutations account for 
about 10% of PPB cases
In twelve children, we identified biallelic DICER1 mutations 
present at high allele frequencies in a PPB tumor, but not detect-
able in blood even with the benefit of high-depth NGS (Table S8). 
Tumors from these children had an RNase IIIb hotspot missense 
mutation and either a nonsense LOF mutation (n = 5) or allele loss 
(n = 7). All twelve children presented with a single PPB tumor 
and none developed additional foci of disease in the lungs or other 
organs over the course of subsequent follow-up. This is consistent 
with occurrence of both an RNase IIIb hotspot mutation and a LOF 
mutation or allele loss within a single, highly localized clone of 
somatic cells which then gave rise to the tumor. Absence of addi-
tional disease foci is a predictable outcome if both DICER1 muta-
tions are restricted to the initial site of tumorigenesis. However, the 
absence of additional disease foci among children in this category 
did not indicate less dangerous disease. Of the 12 patients, 11 had 
advanced PPB (type II or III), and two succumbed (Table 1).
Currently unresolved cases
Twelve PPB probands in our cohort are negative for predisposing 
DICER1 mutations detectable in blood DNA by Sanger sequencing 
or NGS of coding exons. Ten of these children had a single focus of 
disease, and thus may be sporadic cases involving tumor-specific, 
biallelic DICER1 mutations, but tumor tissue is either not avail-
able or not of sufficient quality for confirmation. Two had multifo-
cal disease, possibly reflecting DICER1 mosaicism that is not well 
represented in the blood lineage (below our limits of detection). 
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Clinical features of the twelve unresolved cases and the status of 
further analyses pending or completed, including tumor sequenc-
ing, NanoString copy number assay and germline sequencing for 
additional candidate loci, are summarized in Table S9.
Dataset 1. Patient information dataset
http://dx.doi.org/10.5256/f1000research.6746.d80768
Excel file with deidentified raw data for patient ages at diagnosis 
and numbers of disease foci, and statistical analyses51.
Discussion
Genotype-phenotype correlation of predisposing mutations 
in PPB-DICER1 syndrome
All germline DICER1 truncating mutations are predicted to be 
essentially equivalent in their effect: complete loss of function in 
miRNA processing. This prediction is based partly on nonsense-
mediated decay, but also reflects the functional domain structure 
of the DICER1 protein. All truncating mutations so far identified 
in PPB/DICER1 syndrome patients interrupt the open reading 
frame before the end of the critical RNase IIIb domain (Figure 1, 
Table S3). Neomorphic RNase IIIb domain function (skewed 5p/3p 
miRNA production) is a recurring feature of DICER1 tumors, and it 
is plausible that loss of all wildtype RNase IIIb function is required 
for it to become tumorigenic. Presumed equivalence of all truncat-
ing mutations is consistent with clinical findings: no correlations 
are apparent between locations of germline truncating mutations 
within the DICER1 gene and clinical features such as age of onset, 
number of disease foci, specific tissue sites involved or survival. 
Non-truncating germline mutations are too rare for correlations 
with clinical presentations or outcomes to be ascertained.
The natural history of PPB indicates a multistep genetic pathogen-
esis, and so it is not surprising that in some cases where no germline 
DICER1 mutation can be detected, one of the two “hits” required 
for tumorigenesis was acquired during embryogenesis in the form 
of somatic mosaicism. Mosaic mutations may ultimately prove 
Figure 3. Numbers and types of disease foci in DICER1 syndrome patients with mosaic RNase IIIb domain hotspot mutations. For 
each of the five mosaic hotspot children identified in this study, an individual timeline indicates numbers of discrete foci of neoplastic disease 
and their histopathological types, graphed with respect to patient age at diagnosis. Across the lower portion of the chart, a single aggregate 
timeline (dark violet) represents the mean number of disease foci for all PPB/DICER1 syndrome patients with predisposing loss of function 
(LOF) mutations identified in this study, graphed with respect to patient age at diagnosis. The shaded areas (in lighter violet) surrounding the 
timeline for LOF mutation patients indicates one and two standard deviations above and below the mean. The range of foci number among 
all LOF mutation patients was 0 to 6 in all years of age represented (not shown). Abbreviations: CN cystic nephroma; CBME ciliary body 
medulloepithelioma (eye); NCMH nasal chondromesenchymal hamartoma; PPB pleuropulmonary blastoma, PinB pineoblastoma; SIP small 
intestinal polyp(s); SLCT Sertoli-Leydig cell tumor (ovary); TCa thyroid carcinoma; TN thyroid nodule(s).
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important in the pathogenesis of many other sporadic childhood 
neoplasias, as demonstrated recently for retinoblastoma (RB1)43.
Mosaicism for RNase IIIb domain hotspot missense mutations 
defines a special category of DICER1 syndrome patients that are 
phenotypically distinct from those who bear germline or mosaic 
LOF mutations. RNAse IIIb hotspot mutations have not been 
encountered as inherited alleles in this study or others, which sug-
gests they are inviable4,8,10,11,14–16,21,26–30,34,44. In addition to the five 
mosaic RNase IIIb hotspot patients in our cohort, three apparently 
similar cases have been reported (Table 2). Klein et al. described 
two infants with bilateral Wilms tumor and multiple cysts of the 
kidneys and lungs44. Each child was found to be mosaic for a 
DICER1 RNase IIIb domain missense mutation, although in one 
case the mutation was at D1713; also an acidic residue within the 
RNase IIIb catalytic cleft, but not an established hotspot. De Kock 
et al. described an infant with pituitary blastoma and bilateral cysts 
of the kidneys and lungs in whom a de-novo hotspot mutation was 
detected at high allele frequency in blood as well as tumor11.
Clinically, mosaic hotspot patients are distinguished by two fea-
tures: i.) consistently early presentations of neoplastic disease, often 
by one year of age, and ii.) numerous discrete foci of disease devel-
oped concurrently or successively, usually involving more than one 
syndromic tissue/organ site (Figure 3, Table 2). The two features 
are related and can be interpreted within the conceptual framework 
of the emerging model for DICER1 syndrome pathogenesis, which 
provides important insight as to how tumor suppression by DICER1 
fails6,26,33,35,36. DICER1 is not a classical tumor suppressor gene for 
which “two hits” – loss of function in both alleles – are required 
to allow tumorigenesis. Neither is it haploinsufficient in the usual 
sense, i.e., that cells with only one expressed allele make wild-type 
protein, but not in sufficient quantity to fulfill its function. Rather, 
it is neomorphic function by mutant DICER1 protein, with substi-
tutions of key amino acids in the RNase IIIb domain that causes 
tumor suppression to falter when it is not masked by expression of 
wild-type DICER1 protein. Unmasking of an RNase IIIb hotspot 
mutation may arise through any form of LOF mutation in the wild 
type allele, including allele loss. The two mutational events, RNase 
IIIb missense and LOF, may occur in either order and both are gen-
erally required to foment the initiation of tumorigenesis. However, 
as outlined below, RNase IIIb hotspot mutation is a low-probability 
event and LOF mutation is, relatively, a very high-probability event. 
The projected consequence of these lopsided probabilities is that 
occurrence of an RNase IIIb hotspot mutation becomes the rate-
limiting step in onset of pathogenesis.
Rationale for the distinctive phenotype of mosaicism for 
RNase IIIb hotspot mutations
The RNase IIIb domain hotspots in DICER1 are a diminutive 
mutational target; five codons within an open reading frame of 
1922 codons (0.26%). Moreover, molecular mechanisms by which 
RNase IIIb hotspot missense mutations can arise are restricted to 
errors of DNA replication and/or DNA repair that produce nucle-
otide substitution without disturbing the open reading frame. There 
are 36 possible single-nucleotide changes that can produce amino 
acid substitutions at these five codons, and only a subset of them has 
ever been identified in DICER1 syndrome tumors. The spectrum 
of pathogenic RNase IIIb hotspot mutations is thus very narrow. 
In contrast, the spectrum of possible LOF mutations is broad and 
mechanistically diverse. Of the 1922 codons in the DICER1 open 
reading frame, 675 can be converted to a stop codon by a single 
nucleotide change. A subset can be converted in more than one way, 
giving a total of 736 possible single nucleotide changes that result 
in a nonsense mutation. Among the other 16,562 possible single 
nucleotide changes in the DICER1 open reading frame, presumably 
some would be missense mutations that disrupt DICER1 protein 
function. The five non-hotspot missense mutations we detected as 
predisposing alleles in PPB probands are likely examples (Figure 2). 
The individual nucleotides of the DICER1 open reading frame 
present 5766 point locations at which insertion or deletion of one 
or a few nucleotides can shift reading frame. An additional 104 
bases comprise canonical splice sites of the 26 DICER1 introns, 
where small sequence changes may result in exon skipping, with 
or without frameshift. The possibilities for LOF mutations also 
include larger intra-locus deletions and allele loss through copy-
neutral loss of heterozygosity, segmental deletions or complete loss 
of chromosome 14. Absolute frequencies of these diverse DICER1 
mutational mechanisms in a particular cell lineage cannot be mod-
eled precisely, but it becomes clear that the aggregate likelihood of 
all possible LOF mutations is vastly greater than the likelihood of a 
neomorphic mutation in one of the five hotspot codons.
It follows that in a developing embryo or child with a germline 
(or mosaic) DICER1 LOF mutation, “second hits” occurring in a 
somatic cell will almost always be another LOF mutation, usually 
resulting in cell death or limited proliferation at most. Rarely, a sec-
ond hit will be an RNase IIIb hotspot missense mutation, which 
allows for continuing cell viability and growth, though at the cost 
of skewed miRNA processing that may ultimately promote tumori-
genesis in the surviving clones of cells. However, the low likelihood 
of incurring an RNase IIIb hotspot missense mutation in somatic 
cells means that months, years or a lifetime may elapse before 
one occurs. Further, the developmental context in which a second, 
hotspot mutation occurs may be important. There are apparently 
windows of risk for transformation, perhaps coinciding with cer-
tain periods of organ/tissue development when an “onco-fetal” gene 
program is normally active and subject to miRNA modulation, i.e., 
lung, kidney and brain in the embryo; uterine cervix and ovaries in 
pubertal girls1–3,8,9,45. A low probability of RNase IIIb hotspot muta-
tions as second hits during windows of risk may underlie the low 
penetrance and variable expression of familial LOF mutations in 
DICER1 syndrome.
For a developing child with a mosaic RNase IIIb hotspot mutation, 
the prospects are radically different. Somatic cells that bear the 
RNase IIIb hotspot mutation, masked by a wild type allele, will be 
viable and non-tumorigenic unless and until they sustain a second 
hit. However, cells with a preexisting RNase IIIb hotspot mutation 
are at high aggregate risk of acquiring a subsequent LOF muta-
tion, because it can take any of the myriad forms outlined above. 
The probability of a secondary LOF mutation occurring during 
expansion of any given cell lineage over the course of prenatal and 
postnatal development is relatively high, and independent LOF 
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mutations in multiple lineages may occur. If sufficient fractions of 
cells in critical lineages are affected, disturbed regulation of devel-
opmental gene expression programs arising from defective miRNA 
processing may be lethal in utero. For surviving embryos, onsets of 
tumorigenesis will tend to be early and, depending on embryonic 
distribution of the RNase IIIb hotspot mutation, foci of tumorigen-
esis may arise in one or more organ sites characteristic of DICER1 
syndrome. Additionally, we hypothesize that in mosaic hotspot chil-
dren, wider tissue/organ distribution of aberrant miRNA processing 
during development may produce syndromic features not seen in 
children with predisposing LOF mutations, such as juvenile-type 
small intestinal polyps, or the generalized somatic overgrowth 
noted by Klein et al44.
Implications for mutation testing, clinical evaluation, and 
genetic counseling
Recent publications have outlined general recommendations for 
mutation detection and clinical evaluation for syndromic dis-
ease in patients with suspected DICER1 syndrome and family 
members9,46–48. Here we add considerations of risk for multifocal 
disease and reproductive transmission of DICER1 mutations based 
on mutation category.
Most predisposing DICER1 mutations are germline and detectable 
by targeted Sanger sequencing from blood. Initial testing should 
include parents, to distinguish inherited from de novo mutations. 
Sanger sequencing will usually suffice to detect a parental mutation 
that is also constitutional, but may fail to detect mosaicism. There is 
growing appreciation that apparently de novo mutations in children 
with genetic disease sometimes stem from mosaicism in a parent, 
which can often be detected by more sensitive methods49. For eight 
patients with apparently de novo mutations in this cohort, we found 
no evidence of mosaicism in parents by resequencing with high-
depth NGS, but this limited finding does not exclude the possibility 
of parental mosaicism for families evaluated in the future.
For those patients who have a tumor with confirmed DICER1 
mutation(s), but test negative for germline mutation by Sanger 
sequencing from blood, it will be important to distinguish as rigor-
ously as possible between tumor-specific, biallelic mutations and 
the presence of underlying mosaicism. Mutations confined to the 
tumor will confer no risk for new foci of primary disease in the 
proband, and family members including potential offspring will be 
unaffected. Mosaicism, whether for an LOF mutation or an RNase 
IIIb hotspot mutation, will confer some degree of risk for additional 
syndromic neoplasias. It may be impossible to unequivocally rule 
out mosaicism, but techniques such as targeted resequencing by 
high depth NGS in multiple tissues can greatly improve diagnostic 
confidence, particularly with respect to RNase IIIb hotspot muta-
tions. For patients who have more than one focus of disease but no 
germline or mosaic LOF mutation identifiable by targeted NGS of 
exons, testing for intragenic deletions or larger genomic alterations 
is recommended.
Patients carrying mosaic RNase IIIb hotspot mutations are pre-
dicted, on the basis of both clinical observations and mechanistic 
rationale, to have extraordinarily high risk as a group for developing 
multiple disease foci; approaching 100%. It will not be possible to 
predict individual risk for multifocal disease by allele frequency 
in blood, as this will not reveal the extent to which other somatic 
lineages harbor the mutation. Mosaic RNase IIIb hotspot patients 
will benefit from the most proactive program of family education 
and surveillance. The International PPB Registry recommends that 
potential benefits of renal ultrasound and surveillance chest CT be 
discussed with the family48. The frequency of follow-up chest CTs 
and chest radiographs should be determined individually, based on 
patient age, medical history and previous imaging results. Continu-
ing evaluations should include a yearly complete review of systems 
by a clinician familiar with DICER1 syndrome; yearly screening 
for ovarian SLCT with review of systems for endocrine dysfunction 
and pelvic ultrasound for females from early childhood through 
adulthood; yearly ophthalmologic examination and yearly thyroid 
examination by palpation and/or ultrasound. Pituitary blastoma and 
pineoblastoma are rare even in DICER1 syndrome and typically 
limited to the infant and young child. There is no consensus at this 
time on screening for intracranial neoplasms.
As prospective parents, patients who are mosaic for a DICER1 
mutation face a theoretical risk for transmitting the mutation of up 
to 50%, depending upon whether and at what frequency it is present 
in germ cells. For carriers of a mosaic LOF mutation, the conse-
quences of transmission will be similar to those of a germline LOF 
mutation carrier. For carriers of a mosaic RNase IIIb mutation, it 
is uncertain whether transmission could result in a live birth. The 
absence of RNase IIIb hotspot mutations as inherited alleles in all 
published studies implies they preclude development to term, but 
this remains speculative. The mosaic hotspot mutation identified 
in patient 101 of this cohort was discernable in blood by Sanger 
sequencing and present at 15% of NGS read counts in normal 
lymph node tissue (Table 2). Similarly in the two Wilms tumor 
patients reported by Klein et al. and one pituitary blastoma patient 
described by De Kock et al., de-novo hotspot mutations were read-
ily detected in blood by Sanger sequencing44,11. Whether the lat-
ter case is truly germline or mosaic with high representation in the 
blood lineage was unclear. Nonetheless, it is clear from these exam-
ples that human embryogenesis can tolerate a DICER1 hotspot 
mutation at high allele frequency in at least some cell lineages. It 
thus seems possible, though unlikely, that an inherited RNAse IIIb 
hotspot mutation could be viable.
Data availability
The ClinVar accession number(s) for the variant sequences reported 
in this paper are SCV000195560-SCV000195643.




Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org/
PPB Genetic Study In: Clinical Trials.Gov available from, http://
clinicaltrials.gov/show/NCT00565903
Page 12 of 21
F1000Research 2015, 4:214 Last updated: 24 JUL 2015
International PPB Registry, http://www.ppbregistry.org
NCI DICER1 Phenotype Study, http://dceg.cancer.gov/research/
clinical-studies/DICER1-ppb-study
Author contributions
DAH, YM, GW, LPD, JI and PG conceived the study. DAH, AF, 
JY, WY, AR designed the experiments. DAH, AF, JY, AR, PS, LD, 
GW carried out the research. CR, GW, AH, KPS contributed data-
base support and analysis. DRS, MAB and JT provided expertise in 
genetics. HG performed statistical analysis. DAH and MAB inter-
preted the results and prepared the first draft of the manuscript. All 
authors were involved in the revision of the draft manuscript and 
have agreed to the final content.
Competing interests
No competing interests were disclosed.
Grant information
Investigators were supported by NCI R01CA143167 (DAH, LD, 
CTR, LPD) an American Society of Clinical Oncology Young 
Investigator Award (LD), The Parson’s Foundation (DAH), Hyundai 
Hope on Wheels (LD, KAS), a St. Baldrick’s fellowship (KAS), 
The Children’s Discovery Institute at St. Louis Children’s Hospi-
tal (DAH) The Hope Street Kids Foundation (DAH), Washington 
University Department of Pathology and Immunology (DAH, LPD) 
and St. Louis Children’s Hospital Foundation (DAH). The Inter-
national PPB Registry is supported by the Pine Tree Apple Tennis 
Classic, the Theodora H. Lang Charitable Trust, the Children’s 
Hospitals and Clinics of Minnesota Foundation, and the Randy 
Shaver Community Cancer Fund. This work was also supported 
in part by the Hereditary Cancer, Multiplexed Gene Analysis and 
Tissue Procurement core facilities of the Alvin J. Siteman Cancer 
Center (NCI Cancer Center Support Grant #P30 CA91842) and by 
the Division of Cancer Epidemiology and Genetics (DCEG) of the 
National Cancer Institute Intramural Research Program (DRS).
I confirm that the funders had no role in study design, data collection 
and analysis, decision to publish, or preparation of the manuscript.
Acknowledgements
The authors thank the families of children with PPB and their many 
physicians and research associates, who donated time and energy to 
provide samples for the study.
Supplemental data
Supplemental data for ‘Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in 
DICER1 syndrome: a unique variant of the two-hit tumor suppression model’.
Supplemental data file comprises nine tables:
Table S1. DICER1 coding region amplicons for Ion Torrent sequencing
Table S2. DICER1 probes for NanoString copy number assays
Table S3. Summary of germline DICER1 loss-of-function mutations identified in PPB children
Table S4. Germline missense DICER1 mutations (non-hotspot) – additional details
Table S5. Clinical features of children with germline DICER1 mutations
Table S6. Summary of somatic DICER1 RNase IIIb domain “hotspot” mutations identified
Table S7. Sequence results from children with mosaic DICER1 loss of function mutation
Table S8. Sequence results from children with tumor specific, biallelic DICER1 mutations
Table S9. Clinical features of 12 unresolved cases; PPB children who tested negative for germline DICER1 mutation
Click here to access the data.
Page 13 of 21
F1000Research 2015, 4:214 Last updated: 24 JUL 2015
References
1. Messinger YH, Stewart DR, Priest JR, et al.: Pleuropulmonary blastoma: a report 
on 350 central pathology-confirmed pleuropulmonary blastoma cases by 
the International Pleuropulmonary Blastoma Registry. Cancer. 2015; 121(2): 
276–85.  
PubMed Abstract | Publisher Full Text | Free Full Text 
2. Priest JR, McDermott MB, Bhatia S, et al.: Pleuropulmonary blastoma: a 
clinicopathologic study of 50 cases. Cancer. 1997; 80(1): 147–161.  
PubMed Abstract | Publisher Full Text
3. Hill DA, Jarzembowski JA, Priest JR, et al.: Type I pleuropulmonary 
blastoma: pathology and biology study of 51 cases from the international 
pleuropulmonary blastoma registry. Am J Surg Pathol. 2008; 32(2): 282–295.  
PubMed Abstract | Publisher Full Text 
4. Hill DA, Ivanovich J, Priest JR, et al.: DICER1 mutations in familial 
pleuropulmonary blastoma. Science. 2009; 325(5943): 965.  
PubMed Abstract | Publisher Full Text | Free Full Text 
5. Wagh PK, Gardner MA, Ma X, et al.: Cell- and developmental  
stage-specific Dicer1 ablation in the lung epithelium models cystic 
pleuropulmonary blastoma. J Pathol. 2015; 236(1): 41–52.  
PubMed Abstract | Publisher Full Text | Free Full Text 
6. Pugh TJ, Yu W, Yang J, et al.: Exome sequencing of pleuropulmonary blastoma 
reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in 
retention of 5p-derived miRNA hairpin loop sequences. Oncogene. 2014; 
33(45): 5295–302.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7. Boman F, Hill DA, Williams GM, et al.: Familial association of pleuropulmonary 
blastoma with cystic nephroma and other renal tumors: a report from the 
International Pleuropulmonary Blastoma Registry. J Pediatr. 2006; 149(6): 
850–854.  
PubMed Abstract | Publisher Full Text 
8. Doros L, Yang J, Dehner L, et al.: DICER1 mutations in embryonal 
rhabdomyosarcomas from children with and without familial PPB-tumor 
predisposition syndrome. Pediatr Blood Cancer. 2012; 59(3): 558–560.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Doros L, Schultz KA, Stewart DR, et al.: DICER1-related disorders. In 
GeneReviews® [Internet], R.A. Pagon, ed. Seattle (WA): University of Washington, 
Seattle 1993–2015. 2014.  
PubMed Abstract 
10. Foulkes WD, Bahubeshi A, Hamel N, et al.: Extending the phenotypes associated 
with DICER1 mutations. Hum Mutat. 2011; 32(12): 1381–4.  
PubMed Abstract | Publisher Full Text 
11. de Kock L, Sabbaghian N, Plourde F, et al.: Pituitary blastoma: a pathognomonic 
feature of germ-line DICER1 mutations. Acta Neuropathol. 2014; 128(1): 111–122. 
PubMed Abstract | Publisher Full Text | Free Full Text 
12. McDermott MB, Ponder TB, Dehner LP: Nasal chondromesenchymal hamartoma: 
an upper respiratory tract analogue of the chest wall mesenchymal 
hamartoma. Am J Surg Pathol. 1998; 22(4): 425–433.  
PubMed Abstract 
13. Priest JR, Williams GM, Manera R, et al.: Ciliary body medulloepithelioma: 
four cases associated with pleuropulmonary blastoma--a report from the 
International Pleuropulmonary Blastoma Registry. Br J Ophthalmol. 2011; 95(7): 
1001–1005.  
PubMed Abstract | Publisher Full Text 
14. Slade I, Bacchelli C, Davies H, et al.: DICER1 syndrome: clarifying the diagnosis, 
clinical features and management implications of a pleiotropic tumour 
predisposition syndrome. J Med Genet. 2011; 48(4): 273–278.  
PubMed Abstract | Publisher Full Text 
15. Stewart DR, Messinger Y, Williams GM, et al.: Germline and somatic DICER1 
mutations in nasal chondromesenchymal hamartoma. J Med Genet. 2014; 133: 
1443–1450. 
16. Wu MK, Sabbaghian N, Xu B, et al.: Biallelic DICER1 mutations occur in Wilms 
tumours. J Pathol. 2013; 230(2): 154–164.  
PubMed Abstract | Publisher Full Text 
17. Bal N, Kayaselçuk F, Polat A, et al.: Familial cystic nephroma in two siblings 
with pleuropulmonary blastoma. Pathol Oncol Res. 2005; 11(1): 53–56.  
PubMed Abstract | Publisher Full Text 
18. Bhardwaj AK, Sharma PD, Mittal A, et al.: Bilateral cystic nephroma with 
pleuropulmonary blastoma. BMJ Case Rep. 2011; 2011: pii: bcr0520114171.  
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Bouron-Dal Soglio D, Harvey I, Yazbeck S, et al.: An association of 
pleuropulmonary blastoma and cystic nephroma: possible genetic 
association. Pediatr Dev Pathol. 2006; 9(1): 61–64.  
PubMed Abstract | Publisher Full Text 
20. Delahunt B, Thomson KJ, Ferguson AF, et al.: Familial cystic nephroma and 
pleuropulmonary blastoma. Cancer. 1993; 71(4): 1338–1342.  
PubMed Abstract | Publisher Full Text 
21. de Kock L, Sabbaghian N, Druker H, et al.: Germ-line and somatic DICER1 
mutations in pineoblastoma. Acta Neuropathol. 2014; 128(4): 583–595.  
PubMed Abstract | Publisher Full Text | Free Full Text 
22. Kousari YM, Khanna G, Hill DA, et al.: Case 211: pleuropulmonary blastoma in 
association with cystic nephroma-DICER1 syndrome. Radiology. 2014; 273(2): 
622–625.  
PubMed Abstract | Publisher Full Text 
23. López-Andreu JA, Ferrís J, Esquembre C, et al.: Familial cystic nephroma and 
pleuropulmonary blastoma. Cancer. 1993; 72(9): 2792–2793.  
PubMed Abstract | Publisher Full Text 
24. Schultze-Florey RE, Graf N, Vorwerk P, et al.: DICER1 syndrome: a new cancer 
syndrome. Klin Padiatr. 2013; 225(3): 177–178.  
PubMed Abstract | Publisher Full Text 
25. Shaheen IS, Fitzpatrick M, Brownlee K, et al.: Bilateral progressive cystic 
nephroma in a 9-month-old male infant requiring renal replacement therapy. 
Pediatr Nephrol. 2010; 25(9): 1755–1758.  
PubMed Abstract | Publisher Full Text 
26. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al.: Recurrent somatic DICER1 
mutations in nonepithelial ovarian cancers. N Engl J Med. 2012; 366(3): 234–242. 
PubMed Abstract | Publisher Full Text 
27. Rio Frio T, Bahubeshi A, Kanellopoulou C, et al.: DICER1 mutations in familial 
multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA. 
2011; 305(1): 68–77.  
PubMed Abstract | Publisher Full Text | Free Full Text 
28. Schultz KA, Yang J, Doros L, et al.: DICER1-pleuropulmonary blastoma 
familial tumor predisposition syndrome: a unique constellation of neoplastic 
conditions. Pathol Case Rev. 2014; 19(2): 90–100.  
PubMed Abstract | Publisher Full Text | Free Full Text 
29. Witkowski L, Mattina J, Schönberger S, et al.: DICER1 hotspot mutations in non-
epithelial gonadal tumours. Br J Cancer. 2013; 109(10): 2744–50.  
PubMed Abstract | Publisher Full Text | Free Full Text 
30. Doros LA, Rossi CT, Yang J, et al.: DICER1 mutations in childhood cystic 
nephroma and its relationship to DICER1-renal sarcoma. Mod Pathol. 2014; 
27(9): 1267–80.  
PubMed Abstract | Publisher Full Text | Free Full Text 
31. Bernstein E, Caudy AA, Hammond SM, et al.: Role for a bidentate ribonuclease 
in the initiation step of RNA interference. Nature. 2001; 409(6818): 363–366.  
PubMed Abstract | Publisher Full Text 
32. Denli AM, Tops BB, Plasterk RH, et al.: Processing of primary microRNAs by the 
Microprocessor complex. Nature. 2004; 432(7014): 231–235.  
PubMed Abstract | Publisher Full Text 
33. Anglesio MS, Wang Y, Yang W, et al.: Cancer-associated somatic DICER1 
hotspot mutations cause defective miRNA processing and reverse-strand 
expression bias to predominantly mature 3p strands through loss of 5p strand 
cleavage. J Pathol. 2013; 229(3): 400–409.  
PubMed Abstract | Publisher Full Text 
34. de Kock L, Plourde F, Carter MT, et al.: Germ-line and somatic DICER1 mutations 
in a pleuropulmonary blastoma. Pediatr Blood Cancer. 2013; 60(12): 2091–2092.  
PubMed Abstract | Publisher Full Text 
35. Seki M, Yoshida K, Shiraishi Y, et al.: Biallelic DICER1 mutations in sporadic 
pleuropulmonary blastoma. Cancer Res. 2014; 74(10): 2742–9.  
PubMed Abstract | Publisher Full Text 
36. Gurtan AM, Lu V, Bhutkar A, et al.: In vivo structure-function analysis of human 
Dicer reveals directional processing of precursor miRNAs. RNA. 2012; 18(6): 
1116–1122.  
PubMed Abstract | Publisher Full Text 
37. Robinson JT, Thorvaldsdóttir H, Winckler W, et al.: Integrative genomics viewer. 
Nat Biotechnol. 2011; 29(1): 24–26.  
PubMed Abstract | Publisher Full Text | Free Full Text 
38. Thorvaldsdóttir H, Robinson JT, Mesirov JP: Integrative Genomics Viewer (IGV): 
high-performance genomics data visualization and exploration. Brief Bioinform. 
2013; 14(2): 178–192.  
PubMed Abstract | Publisher Full Text | Free Full Text 
39. Hu J, Ng PC: SIFT Indel: predictions for the functional effects of amino acid 
insertions/deletions in proteins. PLoS One. 2013; 8(10): e77940.  
PubMed Abstract | Publisher Full Text | Free Full Text 
40. Ng PC, Henikoff S: SIFT: Predicting amino acid changes that affect protein 
function. Nucleic Acids Res. 2003; 31(13): 3812–3814.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41. Sim NL, Kumar P, Hu J, et al.: SIFT web server: predicting effects of amino 
acid substitutions on proteins. Nucleic Acids Res. 2012; 40(Web Server issue): 
W452–W457.  
PubMed Abstract | Publisher Full Text | Free Full Text 
42. Sabbaghian N, Srivastava A, Hamel N, et al.: Germ-line deletion in DICER1 
revealed by a novel MLPA assay using synthetic oligonucleotides.  
Eur J Hum Genet. 2014; 22(4): 564–567.  
PubMed Abstract | Publisher Full Text | Free Full Text 
43. Chen Z, Moran K, Richards-Yutz J, et al.: Enhanced sensitivity for detection of 
low-level germline mosaic RB1 mutations in sporadic retinoblastoma cases 
using deep semiconductor sequencing. Hum Mutat. 2014; 35(3): 384–391.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 14 of 21
F1000Research 2015, 4:214 Last updated: 24 JUL 2015
44. Klein S, Lee H, Ghahremani S, et al.: Expanding the phenotype of mutations 
in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 
cause GLOW syndrome. J Med Genet. 2014; 51(5): 294–302.  
PubMed Abstract | Publisher Full Text | Free Full Text 
45. Dehner LP, Jarzembowski JA, Hill DA: Embryonal rhabdomyosarcoma of 
the uterine cervix: a report of 14 cases and a discussion of its unusual 
clinicopathological associations. Mod Pathol. 2012; 25(4): 602–14.  
PubMed Abstract | Publisher Full Text 
46. Foulkes WD, Priest JR, Duchaine TF: DICER1: mutations, microRNAs and 
mechanisms. Nat Rev Cancer. 2014; 14(10): 662–672.  
PubMed Abstract | Publisher Full Text 
47. Samuel N, Villani A, Fernandez CV, et al.: Management of familial cancer: 
sequencing, surveillance and society. Nat Rev Clin Oncol. 2014; 11(12): 
723–31.  
PubMed Abstract | Publisher Full Text 
48. Schultz KA, Harris A, Williams GM, et al.: Judicious DICER1 testing and 
surveillance imaging facilitates early diagnosis and cure of pleuropulmonary 
blastoma. Pediatr Blood Cancer. 2014; 61(9): 1695–1697.  
PubMed Abstract | Publisher Full Text | Free Full Text 
49. Campbell IM, Yuan B, Robberecht C, et al.: Parental somatic mosaicism is 
underrecognized and influences recurrence risk of genomic disorders.  
Am J Hum Genet. 2014; 95(2): 173–182.  
PubMed Abstract | Publisher Full Text | Free Full Text 
50. Bragg LM, Stone G, Butler MK, et al.: Shining a light on dark sequencing: 
characterising errors in Ion Torrent PGM Data. PLoS Comput Biol. 2013; 9(4): 
e1003031.  
PubMed Abstract | Publisher Full Text | Free Full Text 
51. Brenneman M, Field A, Yang J, et al.: Dataset 1 in: Temporal order of RNase IIIb 
and loss-of-function mutations during development determines phenotype in 
DICER1 syndrome: a unique variant of the two-hit tumor suppression model. 
F1000Research. 2015.  
Data Source
Page 15 of 21
F1000Research 2015, 4:214 Last updated: 24 JUL 2015
F1000Research
Open Peer Review
 Current Referee Status:
Version 1
 24 July 2015Referee Report
doi:10.5256/f1000research.7245.r9442
,  Julian A. Martinez-Agosto Steven Klein
Departments of Pediatrics and Human Genetics, David Geffen School of Medicine, University of
California, Los Angeles, Los Angeles, CA, USA
Brenneman present an observational study on a cohort of patients with DICER1 Syndrome. Theet al. 
analysis of 124 probands in combination with available familial data increases the understanding of
penetrance and variability of mutations in DICER1 and the effect of these mutations on phenotype. Their
identification of additional mosaic, germline and sporadic mutations helps to further elucidate phenotypic
differences between these groups and provides insight into disease pathogenesis. Their proposed
temporal model of mutation acquisition correlating to disease presentation is supported by the data.




On page two the authors state: “A final category of patients lack predisposing germline or mosaic
mutations and have disease limited to a single PPB tumor bearing tumor-specific RNase IIIb and LOF
mutations.”
Cases with a single PPB tumor should not be included under the umbrella of the DICER1 syndrome. A
single tumor bearing a causative mutation does not merit inclusion as syndromic, which requires wide
spread distribution of mutations in that same gene. This classification is not accurate as these patients
simply represent a sporadic neoplasm.
Subjects and Methods: 
 
Mutation Testing 
On page three the authors state: “Initial sequencing of blood and saliva DNA samples was by standard
Sanger methods described previously or by a commercial laboratory (Ambry Genetics, Aliso Viejo, CA).
Low-frequency variants were detected and quantified by targeted next-generation sequenc- ing (NGS)
using a custom multiplex PCR panel for coding regions (Ion Torrent Ampliseq, Life Technologies,DICER1 
Grand Island, NY, USA). NGS was performed on an Ion Torrent 318 v2 chip (ION PGM Sequencing 200
kit v2, Life Technologies) with an average of 6 samples per chip, to achieve an average depth of coverage
of 3000 filtered reads.”
Did the authors use the Ion Torrent PCR panel for the analysis of the isolated tumors? This is not
mentioned in the methods section. The data presented in Table 2 displays a large distribution in read
numbers, which may have implications for data analysis. Can the authors provide an explanation for the
wide distribution of read coverage in this table, particularly in the disparity of reads between blood and
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numbers, which may have implications for data analysis. Can the authors provide an explanation for the
wide distribution of read coverage in this table, particularly in the disparity of reads between blood and
tumor samples? This should be included in the methods section.
 
Annotation of sequence variants and the spectrum of possible mutations
On page three the authors state their methods for annotating variants identified: “For variants assayed by
NGS, allele frequencies were calculated from filtered read counts. The SIFT algorithm was used to
assess potential significance of novel missense mutations.”
 
It would be helpful, and strengthen the author’s argument that these mutations are pathogenic, to include
an analysis of the frequency of loss of function (LOF) and hotspot mutations in the population by
determining their minor allele frequency (i.e. using ExAC or 1000 genomes).  
 
NanoString genomic copy number assay 
On page four the authors state: Genomic DNA was fragmented and hybridized using the nCounter Prep “
Station, and hybridization signals quantified using the nCounter Digital Analyzer, according to
NanoString’s recommendations.”
It is stated in this section that hybridization signals were quantified. However, in table two many of the
second hit LOF mutations are simple listed as “allele loss” and not quantified. Can the specific allele
region and its quantification be provided as a percentage of allele loss abundance (as was done in table
S8 for “Informative SNP” in cases 91,111,112)? Without this data it cannot be determined why the hot
spot variant and the allele loss are unequally distributed (cases 104 and 105). Furthermore this would
confirm the tumor purity estimates provided as normal cells should not have loss of the second allele.  As
tumor purity increases so should percentage of allele loss if these mutations are in fact required for tumor
formation. As the table reads now it is implied that the second allele loss is complete (50%) in the tumors
where it was observed. If this is not the case we ask that the loss be quantified and included, otherwise
the “-” should be replaced with “NM” (not measured).
 
Were any positive controls run to confirm the ability to specifically detect copy number events using the
Nanostring assay?  For example, isolating DNA from preserved tumor samples often yields sheared
fragments varying in size, which may hinder probe hybridization across fragments. This may yield false




Most predisposing DICER1 mutations are inherited loss of function (LOF) mutations
On page four the authors state: “Our overall approach to detecting and categorizing predisposing DICER1
mutations in PPB children is shown schematically in Figure 1. We identified germline, heterozygous
DICER1 mutations in 90 of the 124 probands in our cohort (72.6%; Table 1, Table S3).”
Are the identified LOF variants observed in the general population (ExAC, 1000 Genomes)?
 
On page four the authors state: “In all, 84 of 90 germline mutations discovered in patients (93%)DICER1 
truncate the open reading frame before the end of the critical RNase IIIb domain, and are thus predicted
to result in complete loss of DICER1 protein function even if the message escapes nonsense-mediated
decay.”
There is no mention of potential alternative splice isoforms of DICER1, which may be translated despite
the presence of early stop and/or frameshift mutations. This is an oversight especially as there is an
emerging role for a specific splice variant DICER1e (a splice variant composed of only the RNase IIIa, IIIb
and dsRBD domains) in neoplasms. This isoform may utilize a distinct promoter as has been observed for
the glucocorticoid receptor gene ( and not rely on faithful sequence integrity ofRusscher , 2007) et al.
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the glucocorticoid receptor gene ( and not rely on faithful sequence integrity ofRusscher , 2007) et al.
upstream exons. Two independent reports ( and ) have shownCantini , 2014 et al. Hinkal  2011et al.,
increased DICER1e isoforms in oral cancer cells and breast cancer cells respectively. This may be an
important factor in discerning potential sub categories of LOF mutations. If in fact DICER1e plays a
pathogenic role it is possible that alleles bearing early stop and/or frameshift mutations upstream of the
RNaseIIIb domain, which in this study account for 93% of the mutations, are still able to code for this
isoform and contribute to disease. The mechanism for oncogenesis may not require a true loss of function
first hit but the presence of a modified isoform which in combination with a hot spot mutation would lead to
a neomorphic phenotype associated with tumor formation.  The authors should acknowledge this
possibility in the manuscript. 
 
Approximately 10% of predisposing DICER1 mutations are mosaic rather than germline
On page six the authors present table 1 “Clinical and Pathologic Features by Predisposing DICER1
Mutation Category.”
In table 1 there is a single case reported of a germline LOF mutation and a Wilms tumor (WT). Could the
authors speculate on the rarity of WT in their large cohort given the described association of both single
hot spot and biallelic mutations in DICER1 with this tumor type ( ; )?Klein , 2014et al. Wu , 2013et al.
 
On page eight the authors state: “NGS of tumor tissues from these children identified somatic LOF
mutations or allele loss in some but not all specimens, with the caveat that allele loss can be difficult to
detect in specimens with low tumor purity ( , PPB Type Ir, CN and NCMH).”i.e.
 
If the second hit LOF mutation is indeed a “driver” mutation of neoplasm one would expect those
mutations to occur early in tumor formation and then clonally expand and be present in a majority of tumor
cells. The very difficulty to detect these second hit LOF mutations argues that these tumors are in fact
genetically heterogeneous; suggesting that these second hit mutations may represent passenger or
modifying mutations but not drivers. The caveat mentioned supports both the authors’ and the alternative
hypotheses and this should be included as a possible mechanism of pathogenesis.
 
On page eight the authors state: “Four of the five children with mosaic hotspot mutationsDICER1 
presented with cystic PPB (type I/IR) rather than sarcomatous disease (type II or type III) and all five have
survived to date.”
It is surprising that none of the mosaic hot spot cases present with PPB type II/III compared to two thirds
of the germline LOF cases. This is not consistent with the more complicated clinical course and numerous
neoplasms observed in the mosaic cases. Is it possible that the distribution in the tissue ultimately
dictates the severity of the PPB? The authors should discuss as part of their disease model why the
mosaic cases have a more complex clinical course while having more benign lung pathology.
 
On page eight the authors state: “Though all five hotspot mosaic children are alive, their clinical
experiences have been complicated and arduous (Figure 3).”
 
As the authors state, cases with mosaic DICER1 hot spot mutations present with a complex clinical
course. Therefore, including a more detailed clinical description of the five mosaic cases, specifically
paying attention to their phenotype, would strengthen this statement. For example, including growth
parameters as well as developmental and physical exam findings may help to define this subgroup of the
DICER1 syndrome. On page 14 of the supplement a footnote to table S9 mentions “This data set is
limited, pursuant to concerns for potential identification of study participants based on particular
combinations of clinical and pathologic features. Qualified investigators with specific questions about the
study not answered by the data in these tables are invited to contact the International PPB Registry. The
Registry will try to accommodate requests for additional data while preserving protected health
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Registry will try to accommodate requests for additional data while preserving protected health
information.” This concern may be the very reason why more detailed phenotypic data is lacking.
However this limits the ability for the reader to draw genotype-phenotype correlations and to compare
these cases to those already reported in the literature.  We request that at least common clinical findings
shared by mosaic cases (if any) are presented in a table without reference to individual cases. This
should limit the risk of potential identification of study participants.
 
Table 2
On page eight the authors state: “We categorized a mutation detected by NGS as mosaic whenDICER1 
the following criteria were met: The mutation was evidently not a constitutional, germline allele becausei. 
it was present at sub-heterozygous frequency (arbitrarily taken as below 35% of reads) in peripheral blood
and/or other normal tissue samples. The mutation was evidently not specific to a tumor, because theii. 
same mutant allele was detected in one or more normal, non-neoplastic tissue samples, OR, the same
mutant allele was detected in multiple primary tumors arising in different organs.”
 
It is possible that low abundance mutations detected in blood are not present in a blood cell lineage but
may represent metastatic disease (for example in case 102 where the brain tumor is a metastatic event
that originated in the lung PPB)? Furthermore cases 102, 103, 104, and 105 have very low mutation
abundance in blood with cases 103-105 carrying less than 0.3%. These low numbers are perhaps
evidence of unrecognized metastatic disease in these patients, the detection of which has been
previously described ( ). Testing of more “normal” tissues is needed forHaber and  Velculescu, 2014
fulfilling the mosaicism criteria as proposed by the authors. It is more likely that the cases in table 2 have
lower levels of mosaicism limited to a small number of tissues in contrast to other cases with more widely
distributed hot spot mutations (Klein , 2014). Additional phenotypic clinical data for these cases (aset al.
requested above) is needed to properly make a comparison.  
Tumor purity is very low in mosaic cases samples (Table 2), and this is used as an argument for why
second hit mutations are lower in abundance. However, it is also possible that the second hit mutation is
unequally distributed throughout the tumor and in fact absent from some regions of the tumor. This
possibility should be mentioned in the manuscript.
 
Tumor-specific, biallelic DICER1 mutations account for about 10% of PPB cases
On page eight the authors state: “In twelve children, we identified biallelic mutations present atDICER1 
high allele frequencies in a PPB tumor, but not detectable in blood even with the benefit of high-depth
NGS (Table S8).”
These cases likely represent sporadic neoplasm mutations. We question if these cases should be
classified as having the “DICER1 syndrome.” A more clear distinction between isolated PPB and the
“DICER1 Syndrome” should be included.
 
Currently unresolved cases 
On page eight the authors state: “Twelve PPB probands in our cohort are negative for predisposing 
mutations detectable in blood DNA by Sanger sequencing or NGS of coding exons.”DICER1 
The authors include an additional 12 unresolved cases (Table S9). We suggest that a potential etiology
for cases in which DICER1 mutations are absent would be caused by mutations in DROSHA or other
genes involved in the microRNA processing pathway. It has been established that at least in the
pathogenesis of sporadic Wilms tumor RNaseIIIb mutations in DROSHA phenocopy those in DICER1,
although possibly by distinct mechanisms (Rakheja, 2014). While the authors pursued DROSHA testing
via Sanger sequencing exclusively in blood (Table S9 Footnote: “Sanger sequencing in blood DNA for
DROSHA, XPO5, and the DICER1 promoter region”) this approach might have missed low abundance
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DROSHA, XPO5, and the DICER1 promoter region”) this approach might have missed low abundance
mosaic mutations. Furthermore, some of these “unresolved” cases (121, 123 and 124) have been
identified as carrying hot spot mutations in their tumors without the presence of a second hit. This may
illustrate that the hotspot mutations alone may be sufficient for tumorogenesis.
 
On page 5 the authors present Figure 1 “Study Design”
 
After reviewing this cohort we call into question the designation of “unresolved” in one case. We would
like to propose that case 123 is actually mosaic due to the presence of the same hotspot mutation in two
distinct disease foci. This case cannot be excluded as mosaic based on the absence of the mutation in
blood as it is similar to case 105 where the sequencing from blood is not above the error threshold. Case
123 should therefore be moved to table two, and the study design/mosaic criteria amended to classify
case 105 and 123 as mosaic even in the absence of the hotspot mutation in normal tissue.  The absence
of a LOF second hit in the presence of a mosaic hot spot mutation should represent a distinct subset of




Genotype-phenotype correlation of predisposing mutations in PPB-DICER1 syndrome
On page ten the authors state: “All germline truncating mutations are predicted to be essentiallyDICER1 
equivalent in their effect: complete loss of function in miRNA processing.”
As mentioned above this conclusion must be tempered by the possibility of an alternatively spliced variant
of DICER1 that could be expressed despite a truncating mutation upstream of the RNase IIIb domain.  
 
On page ten the authors state: “Neomorphic RNase IIIb domain function (skewed 5p/3p miRNA
production) is a recurring feature of tumors, and it is plausible that loss of all wildtype RNase IIIbDICER1 
function is required for it to become tumorigenic.”
The statement “loss of all wildtype RNase IIIb function is required for it to become tumorigenic” does not
apply to all categories of the DICER1 syndrome. From the data as it is presented in this study the only
category where this can be concluded is from the sporadic tumors, which are distinct from the DICER1
syndrome. In these tumors it is clear from the data in table S8 that all hot spot mutations are accompanied
by LOF mutations with corresponding abundances, which are certainly a characteristic of these
aggressive lung neoplasms. However, we cannot conclude causality for the second hit mutations in all
DICER1 tumors since (1) in the mosaic hot spot cases (Table 2) the observed abundance for the second
LOF hit mutations is always less than the hot spot mutation and (2) there are cases of tumors in this report
that lack a second hit (Case 105: NCMH, Case 123 CN and PPB). A main objection to the analysis and
interpretation of these results is the lack of an explanation for the differences in mutation abundance
between LOF and hot spot mutations within a tumor and the presence of tumors without a second hit. This
raises questions as to whether the LOF mutations are in fact drivers of tumorigenesis or passenger
mutations. Although tumor purity could be partially responsible for these inconsistencies, the data on its
own does not sufficiently establish that these LOF mutations are required for tumor formation in
non-sporadic tumor cases when they are not present in all neoplastic cells.
 
In the model as it is proposed by the authors, cases that are mosaic for RNaseIIIb mutations display no
clinical findings until a second LOF mutation occurs which drives and is essential for tumor formation
(Page 11, last paragraph). We believe there is the possibility for another explanation. A single RNase IIIb
mutation alone could have a pro-onocogenic effect on distinct cell types at specific developmental stages.
As tumorigenesis proceeds, a LOF mutation in the other allele may arise as the tumor drifts, further
aggravating the 5p/3p imbalance in a sub population of tumor cells. Supporting this alternative model,
cases 105, 121, 123 and 124 are reported to have neoplasms with no second hit detected. If this second
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cases 105, 121, 123 and 124 are reported to have neoplasms with no second hit detected. If this second
hit is essential why do these tumors lack the LOF second hits?  In aggregate there are 4 mosaic cases (2
in this report and 2 in the literature), which, in combination with the absence of germline true heterozygote
hot spot mutations, support the alternate model that mosaic hot spot mutations are likely pathogenic on




Table S5 Clinical features of children with germline DICER1 mutations
 
Can the authors comment on why mortality is higher in germline LOF mutation carriers than it is in the
mosaic “hot spot” mutation carriers even though the latter have a more complicated clinical course? Could




The authors should include appropriate references to any manuscripts in which any of these PPB
registry cases have been previously reported. 
While not essential, it would be informative to include any affected siblings for the 10 identified de
LOF cases to support or refute potential germline mosaicism in the parents (Page 4)?novo 
Table 1 includes a single case of a germline LOF mutation and a Wilms tumor (WT). However, little
else is described about this case. Furthermore there is no mention of this case in the
supplementary materials. Please include mutation analysis and additional phenotypic information
for this case. 
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard, however we have significant reservations,
as outlined above.
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